Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.

Observation of primary outcome:

• Overall Survival
• Disease-free survival

Influencing factors that will be observe:

• Sex
• Blood loss
• Time of surgery
• Number of resection and anastomosis
• Peritoneal Index (PI score)
• Cytoreductibility (CCR score)

Inclusion Criteria:

• Peritoneal mesothelioma

Exclusion Criteria:

• Non resectable disease